TLX — Telix Pharmaceuticals Ltd
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2007191 ·
Last close
$11.45
Market Cap
$3.89B
52W High
$13.11
52W Low
$6.28
ADV30
340,517
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 1,361,851,000 | 251,910,000 | 874,176,000 |
| Dec 2025 | — | — | — | — | 1,163,986,000 | 141,866,000 | 748,610,000 |
| Jun 2025 | — | — | — | — | — | 207,156,000 | 768,011,000 |
| Dec 2024 | — | — | — | — | 940,379,000 | 439,999,000 | 587,442,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-154,538,000
Inventory
$37,080,000
Receivables
$138,371,000
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$890,785,024
EBITDA
$69,806,000
Free Cash Flow
$-62,596,000
Enterprise Value
$4,164,115,712
Total Cash
$251,910,000
Total Debt
$579,860,992
Shares Out
339,784,294
Trailing EPS
$0.10
Book Value
$1.44
ROE
7.4%
ROA
2.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 803,794,000 | 18,053,000 | -7,125,000 | 1,163,986,000 | 748,610,000 | 415,376,000 | — |
| Dec 2024 | 516,551,000 | 55,584,000 | 33,685,000 | 940,379,000 | 587,442,000 | 352,937,000 | — |
| Dec 2023 | 332,978,000 | 34,965,000 | 4,208,000 | 277,258,000 | 174,613,000 | 102,645,000 | — |
| Dec 2022 | 108,913,289 | -50,475,530 | -70,804,931 | 173,716,614 | 119,287,862 | 54,428,752 | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.15
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LEGN | Legend Biotech Corp | $3.72B | $19.11 | — |
| ABCL | AbCellera Biologics Inc. | $4.12B | $12.70 | — |
| VKTX | Viking Therapeutics, Inc. | $4.15B | $35.56 | — |
| KNSA | Kiniksa Pharmaceuticals International, plc | $3.63B | $75.08 | — |
| OGN | Organon & Co. | $3.61B | $13.73 | — |
News headlines (Yahoo Finance, 1h cache)
Telix (ASX:TLX) Shares Could Be 42% Undervalued Following Its ITM Deal
2026-09-23 19:15 · Yahoo
Telix Pharmaceuticals (ASX:TLX) ITM Deal Puts Valuation Back In Focus
2026-09-23 12:13 · Yahoo
Telix (TLX) to Buy Germany’s ITM for up to $2.35 Billion to Lock in its Cancer Isotope Supply
2026-09-22 22:52 · Yahoo
Telix Pharmaceuticals (ASX:TLX) Lands $2.35 Billion Deal To Reshape Radiopharmaceutical Reach
2026-09-22 20:17 · Yahoo
Telix Beefs Up Radioisotopes Supply With $2.35 Billion Deal; Shares Crash
2026-09-21 20:14 · Yahoo
Telix to Buy Germany's ITM Isotope in Deal Worth Up to $2.35 Billion
2026-09-21 11:17 · Yahoo
Telix to acquire ITM in deal worth up to $2.35bn
2026-09-21 10:13 · Yahoo
FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara
2026-09-14 10:30 · Yahoo
FDA Approves Telix's Brain Cancer Imaging Drug Pixclara
2026-09-13 22:56 · Yahoo
Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference
2026-09-09 10:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.